Alkermes (ALKS) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Alkermes insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 7 sold $10.6M of ALKS stock on the open market.
Get emailed when insiders cluster-buy stocks like ALKS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ALKS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $83K | 1 |
| Q3 2026 | — | 0 | $4.2M | 10 |
| Q2 2026 | — | 0 | $2.0M | 8 |
| Q1 2026 | — | 0 | $3.5M | 11 |
| Q4 2025 | — | 0 | $787K | 4 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Alkermes plc. insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $10.6M. 32 of 34 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ALKS earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Jul 28, 2026 | +1.5% | Sold $574K | -8.3%S&P -1.3% | -1.9% |
| May 5, 2026 | -1.0% | Sold $438K | +3.4%S&P +2.2% | +21.2% |
| Feb 25, 2026 | -4.2% | Sold $2.4M | -8.0%S&P +0.3% | -4.4% |
| Jan 12, 2026 | +4.0% | Sold $262K | -1.7%S&P -0.0% | +14.2% |
| Oct 28, 2025 | -4.8% | Sold $284K | +5.8%S&P +0.3% | -5.9% |
| Oct 22, 2025 | +1.5% | Sold $284K | -4.5%S&P +0.1% | -4.8% |
| Jul 29, 2025 | -13.6% | None | +6.8%S&P -0.4% | +3.7% |
| May 1, 2025 | +3.0% | None | +10.5%S&P +2.2% | -3.7% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 2SEC | David Joseph GaffinGeneral Counsel | Sell Plan | 2,034221,388 held (−1%) | $41.03 | $83K | -1.0% | — |
| Sep 3SEC | David Joseph GaffinGeneral Counsel | Sell Plan | 2,034223,422 held (−1%) | $48.01 | $98K | -15.4% | — |
| Sep 1SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 9,00065,389 held (−12%) | $46.99 | $423K | -13.6% | — |
| Aug 17SEC | Christian Todd NicholsSvp, Chief Commercial Officer | Sell Plan | 6,912102,857 held (−6%) | $49.19 | $340K | -17.4% | — |
| Aug 17SEC | Christian Todd NicholsSvp, Chief Commercial Officer | Sell Plan | 664102,193 held (−1%) | $49.65 | $33K | -18.2% | — |
| Aug 3SEC | Nancy Lynn Md SnydermanDirector | Sell | 44,47215,395 held (−74%) | $50.35 | $2.2M | -19.3% | — |
| Aug 3SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 9,00069,389 held (−11%) | $48.58 | $437K | -16.4% | — |
| Aug 3SEC | David Joseph GaffinGeneral Counsel | Sell Plan | 2,034225,456 held (−1%) | $48.58 | $99K | -16.4% | — |
| Jul 6SEC | David Joseph GaffinGeneral Counsel | Sell Plan | 2,034227,490 held (−1%) | $54.03 | $110K | -24.8% | — |
| Jul 1SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 8,30074,089 held (−10%) | $51.46 | $427K | -21.1% | — |
| Jul 1SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 70073,389 held (−1%) | $52.13 | $36K | -22.1% | — |
| Jun 12SEC | Christopher I WrightDirector | Sell Plan | 2,00025,680 held (−7%) | $45.10 | $90K | -10.0% | — |
| Jun 4SEC | David Joseph GaffinGeneral Counsel | Sell Plan | 2,034229,524 held (−1%) | $43.05 | $88K | -5.7% | — |
| Jun 1SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 9,00077,389 held (−10%) | $41.67 | $375K | -2.5% | — |
| May 29SEC | Samuel Joseph ParisiVp, Finance (Interim Pao) | Sell | 16,2177,717 held (−68%) | $42.36 | $687K | -4.1% | — |
| May 4SEC | David Joseph GaffinGeneral Counsel | Sell Plan | 2,034231,558 held (−1%) | $33.20 | $68K | +22.3% | — |
| May 1SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 9,00081,389 held (−10%) | $33.40 | $301K | +21.6% | — |
| Apr 6SEC | David Joseph GaffinGeneral Counsel | Sell Plan | 2,034233,592 held (−1%) | $34.57 | $70K | +17.5% | — |
| Apr 1SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 9,00085,389 held (−10%) | $35.51 | $320K | +14.4% | — |
| Mar 4SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 9,00089,389 held (−9%) | $29.72 | $267K | +36.6% | — |
| Mar 4SEC | Samuel Joseph ParisiVp, Finance (Interim Pao) | Sell Plan | 6,8907,717 held (−47%) | $29.29 | $202K | +38.6% | — |
| Mar 4SEC | Christian Todd NicholsSvp, Chief Commercial Officer | Sell Plan | 6,000109,769 held (−5%) | $30.00 | $180K | +35.4% | — |
| Mar 4SEC | David Joseph GaffinGeneral Counsel | Sell Plan | 2,034235,626 held (−1%) | $29.76 | $61K | +36.5% | — |
| Mar 4SEC | David Joseph GaffinGeneral Counsel | Sell Plan | 2,034237,660 held (−1%) | $29.29 | $60K | +38.6% | — |
| Feb 2SEC | Shane CookeDirector | Sell Plan | 32,113103,744 held (−24%) | $34.78 | $1.1M | +16.8% | — |
| Feb 2SEC | Shane CookeDirector | Sell Plan | 29,087135,857 held (−18%) | $34.34 | $999K | +18.3% | — |
| Feb 2SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 5,00061,740 held (−7%) | $34.24 | $171K | +18.6% | — |
| Feb 2SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 4,00057,740 held (−6%) | $33.54 | $134K | +21.1% | — |
| Jan 8SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 5,00061,740 held (−7%) | $30.00 | $150K | +35.4% | — |
| Jan 2SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 4,00061,740 held (−6%) | $28.00 | $112K | +45.0% | — |
| Dec 5SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 3,74865,740 held (−5%) | $30.00 | $112K | +35.4% | — |
| Dec 1SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 4,00065,740 held (−6%) | $29.30 | $117K | +38.6% | — |
| Nov 3SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 9,00069,740 held (−11%) | $30.38 | $273K | +33.7% | — |
| Oct 15SEC | Craig C. HopkinsonEvp R&D, Chief Medical Officer | Sell Plan | 9,00073,740 held (−11%) | $31.53 | $284K | +28.8% | — |
Insiders at Alkermes plc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Craig C. HopkinsonEvp R&D, Chief Medical Officer | — | $3.9M | Sep 1, 2026 | — |
| Nancy Lynn Md SnydermanDirector | — | $2.2M | Aug 3, 2026 | — |
| Shane CookeDirector | — | $2.1M | Feb 2, 2026 | — |
| Samuel Joseph ParisiVp, Finance (Interim Pao) | — | $889K | May 29, 2026 | — |
| David Joseph GaffinGeneral Counsel | — | $735K | Oct 2, 2026 | — |
| Christian Todd NicholsSvp, Chief Commercial Officer | — | $553K | Aug 17, 2026 | — |
| Christopher I WrightDirector | — | $90K | Jun 12, 2026 | — |
ALKS stock: common questions
Are Alkermes plc. insiders buying ALKS stock?
In the past 12 months, 0 insiders reported open-market purchases of ALKS worth $0.
Are Alkermes plc. insiders selling ALKS stock?
7 insiders reported sales worth $10.6M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ALKS's 52-week range?
Over the past year ALKS has traded between $27.20 and $55.22. It last closed at $40.61 on Oct 9, 2026.